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papilloma growth within 3 weeks.
When transgenic mouse skin
was transplanted to non-transgenic
littermates, papillomas began to grow
across the transplant surfaces (Figure 1).
In contrast, no papillomas developed
when the recipient mice were immu-
nized successfully with an HPV8-E6-
DNA vaccine before transplanta-
tion. This is, at best, a long-term
perspective for humans, but work in
this area is worth every effort in view
of the great skin cancer burden
observed in allograft recipients who
are immunosuppressed.
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Itch, Eosinophils, and Autoimmunity:
A Novel Murine Model of Bullous
Pemphigoid
Kim B. Yancey1
Mice carrying a deletion in the NC14A domain of murine type XVII collagen begin
scratching at age 2 months and then develop erosions, subepidermal vesicles,
eosinophil-rich skin infiltrates, and autoantibodies directed against a 180 kDa skin
protein that appears to be type XVII collagen. These mice represent a bullous
pemphigoid animal model featuring pruritus in immunocompetent, mature, and
largely unmanipulated animals.
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Type XVII collagen
Type XVII collagen (also called bullous
pemphigoid antigen 2 ;BPAG2) is a type
II transmembrane protein associated
with hemidesmosome-anchoring fila-
ment complexes and plasma mem-
branes in basal keratinocytes (Franzke
et al., 2005). The cytoplasmic amino
terminus of type XVII collagen consists
of B500 amino acid residues, contain-
ing several potential phosphorylation
sites within its central portion; by
rotary shadowing, the intracytoplasmic
domain of type XVII collagen appears
as a globular head. The extracellular
domain of type XVII collagen
contains 15 interrupted collagenous
segments (coll 1–15); by rotary
shadowing, the extracellular domain of
type XVII collagen appears as a central
rod (corresponding to coll 15) with a
flexible tail (corresponding to coll 1–14)
(Hirako et al., 1996). Immunoelectron
microscopy studies suggest that the rod
portion of type XVII collagen’s
ectodomain (i.e., coll 15) inserts into
the lamina densa and that its carboxy-
terminal flexible tail then loops back
through the lamina densa into the
lamina lucida (Nonaka et al., 2000).
Type XVII collagen occurs in two
forms, a 180kDa full-length protein
and a 120kDa extracellular domain that
is shed from plasma membranes of basal
keratinocytes by proteolysis (Schacke
et al., 1998). Proteolytic processing of
type XVII collagen is mediated by
‘‘sheddases’’ of the disintegrin and
metalloproteinase family. Phosphoryla-
tion of type XVII collagen by ecto-casein
kinase 2 inhibits its proteolysis, a
mechanism whereby the adhesion and
motility of adjacent basal keratinocytes
may be modulated (Zimina et al., 2007).
In epidermal basement membranes
(BMs), the extracellular domain of type
XVII collagen is found as a homotrimer
in which its collagenous domains form a
cross-linked triple helix. The helix forms
independently of amino acid sequences
in its intracellular portion, apparently
organized in a 50 to 30 orientation
using the 16th non-collagenous portion
of the protein (the 16th non- colla-
genous domain of BPAG2 (NC16)) as a
nucleation site. The cytoplasmic
domain of type XVII collagen
associates with BPAG1, integrin b4,
and plectin. The first extracellular
segment of type XVII collagen (i.e.,
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NC16) contains amino acid residues
that bind integrin a6. Immunogold
electron microscopy studies have
suggested that the carboxy terminus of
type XVII collagen interacts with
laminin 332 at the interface of these
two proteins near the junction of the
lamina lucida and the lamina densa.
Type XVII collagen is targeted by
autoantibodies from patients with bullous
pemphigoid (BP), pemphigoid gestationis
(PG), mucous membrane pemphigoid
(MMP), and linear IgA bullous dermatosis
(LABD; Yancey and Egan, 2000). Auto-
antibodies from patients with BP, PG,
and LABD typically target the NC16A
domain of the protein, whereas those
from patients with MMP tend to target
its distal carboxy terminus, as well as
NC16A. Patients with non-Herlitz junc-
tional epidermolysis bullosa often possess
null mutations in the gene encoding type
XVII collagen (COL17A1). These indivi-
duals characteristically demonstrate a
complete lack of type XVII collagen in
their epidermal BM along with a
tendency for skin fragility, subepidermal
blister formation, alopecia, dystrophic
nails, and dental enamel hypoplasia.
Experimental animal models of bullous
pemphigoid
BP is a polymorphic autoimmune
subepidermal blistering disease that
dominates in the elderly (Yancey and
Egan, 2000). Although initial lesions
may consist of urticarial plaques,
most patients eventually develop tense
blisters on the trunk, groin, axillae, and
flexor surfaces. Pruritus may be minimal
or severe in patients with BP; it may
precede the onset of blister formation by
considerable periods of time. Biopsies
of early lesional skin from patients with
BP typically demonstrate subepidermal
vesicles and/or bullae in association
with an eosinophil-rich infiltrate within
and adjacent to the epidermal BM.
Direct immunofluorescence microscopy
of normal-appearing perilesional skin
from BP patients shows in situ deposits
of IgG and C3 in the epidermal BM.
Most BP patients are seropositive for
IgG autoantibodies directed against two
hemidesmosome-associated proteins in
epidermal BM, BPAG1 and BPAG2
(i.e., type XVII collagen) (Yancey,
2005). Autoantibodies against type
XVII collagen (and in particular its
NC16A domain) are thought to have a
key primary role in the pathophysiology
of BP. Passive transfer of patient-derived
or experimental IgG against human
NC16A or its murine homolog elicits
clinical, histologic, and immunopatho-
logic alterations in neonatal humanized
or neonatal BALB/c mice, respectively,
that mimic those seen in patients with
BP (Liu et al., 1993; Nishie et al., 2007).
IgG-induced blister formation in these
animal models is dependent upon
complement activation, degranulation
of dermal mast cells, and generation of
neutrophil-rich infiltrates—the latter
providing sufficient amounts of unrest-
rained neutrophil elastase to degrade
type XVII collagen and produce subepi-
dermal blisters in vivo (Yancey,
2005). These and other thoroughly
characterized experimental murine
models are widely regarded to provide
proof of concept that IgG anti-NC16A
autoantibodies in patients with BP are
pathogenic (reviewed extensively in
Hurskainen et al. (2015)).
To gain insight into the multiple
functions of human type XVII collagen’s
NC16A domain, Hurskainen et al.
(2015) created genetically modified
mice carrying a deletion of the
corresponding NC14A region of murine
type XVII collagen (DNC14A mice;
Hurskainen et al., 2015). Interestingly,
although these mice displayed no gross
phenotypic changes at birth and grew
normally, at 2 to 3 months of age they
developed scratching, crusted erosions,
subepidermal vesicles, eosinophil-rich
skin infiltrates, eosinophilia, elevated
serum IgE levels, and IgG (and IgA)
anti-BM autoantibodies directed against
a 180kDa protein in wild-type (WT) skin
that appears to be type XVII collagen.
Hurskainen et al. (2015) suggest that
DNC14A mice represent a BP-related
mouse model featuring a primary,
disease-related symptom (i.e., pruritus)
in immunocompetent, mature animals
that have not been subjected to passive
transfer of large amounts of exogenous Ig
or repeated bouts of immunization.
Moreover, they point out that future
studies in DNC14A mice may elucidate
the basis for loss of self-tolerance to an
epidermal BM autoantigen, as well the
development of pruritus, eosinophil-rich
skin infiltrates, eosinophilia, and
elevated serum IgE levels like those
seen in patients with BP.
Additional considerations
Although the results by Hurskainen et al.
(2015) are credible and exciting,
several observations and questions
about DNC14A mice are of additional
interest. For example,
1. Why is the amount of type XVII
collagen in DNC14A mice about
half that seen in WT skin, and why
does the relative amount differ so
much in various mice?
Clinical Implications
 At 2 to 3 months of age, mice carrying a deletion of the NC14A region of
murine type XVII collagen (i.e., the murine homolog of human type XVII
collagen’s NC16A (the 16th non-collagenous domain of BPAG2) domain)
develop scratching, subepidermal vesicles, eosinophil-rich skin infiltrates,
eosinophilia, elevated serum IgE levels, and IgG (and IgA) anti-basement
membrane (BM) autoantibodies directed against a 180 kDa protein in wild-
type skin that appears to be type XVII collagen.
 DNC14A mice appear to represent a mouse model of bullous pemphigoid,
featuring a primary, disease-related symptom (i.e., pruritus) in immuno-
competent, mature animals that have not been subjected to passive
transfer of large amounts of exogenous Ig or repeated bouts of
immunization.
 Future studies in DNC14A mice may elucidate the basis of this loss of self-
tolerance to an epidermal BM autoantigen, as well the development of
pruritus, eosinophil-rich skin infiltrates, eosinophilia, and elevated serum
IgE levels that resemble those seen in patients with bullous pemphigoid.
COMMENTARY
1214 Journal of Investigative Dermatology (2015), Volume 135
2. Why is the shed ectodomain of type
XVII collagen detectable in skin
extracts of DNC14A mice?
3. Given that newborn DNC14A mice
display subepidermal microblisters
and rudimentary, malformed hemi-
desmosomes, why are levels of
other adhesion proteins in the epi-
dermal BM not notably reduced
(especially when anchoring fibrils
in DNC14A skin are short, disorga-
nized, and abnormally clustered)?
4. What contributes to the onset of
itch in DNC14A mice? Why does
itch take several months to develop?
Is itch related to humoral immunity
(autoimmunity) and, if so, how?
5. Why do roughly 20% of DNC14A
mice fail to develop scratching?
Does this finding somehow relate
to relative amounts of type XVII
collagen in the skin?
6. What role does repeated injury (i.e.,
scratching) have in loss of self-tol-
erance to the skin?
7. What can be learned from the so-
called healthy skin of adult
DNC14A mice (i.e., the skin remote
from sites scratched—the skin said
not to differ from WT skin)?
8. About 70% of DNC14A ‘‘scratching
mice’’ tested showed the presence
of circulating IgG anti-BM autoanti-
bodies against WT skin. Does the
development and degree (i.e., titer)
of seropositivity in this model cor-
relate with the relative amounts of
type XVII collagen in the skin, the
degree of scratching displayed, or
something else?
9. Why is murine type XVII collagen
(rather than one or more other struc-
tural proteins in epidermal BM) the
target of autoimmunity in this model?
What epitopes within type XVII col-
lagen are targeted? Why do such
autoantibodies fail to elicit comple-
ment deposition in epidermal BM?
10. What mediators elicit elevated levels
of eosinophils and IgE in the skin and
sera of DNC14A ‘‘scratching mice’’?
Conclusion
Deletion of the NC14A domain of type
XVII collagen would be predicted to
yield mice with skin fragility as a con-
sequence of impaired type XVII collagen
in the epidermal BM (e.g., skin contain-
ing type XVII collagen that is not
natively trimerized, processed, or appro-
priately bound to adjacent structural
proteins). Indeed, one might suggest that
the last thing imaginable is that deletion
of the murine homolog of the immuno-
dominant portion of type XVII collagen
results in loss of tolerance to ‘‘modified
self’’ and development of a novel mur-
ine model of BP. Such is the beauty of
DNC14A mice and science itself—good
questions about fundamental biological
processes often yield unexpected
insights and opportunities.
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Autophagy as a Melanocytic
Self-Defense Mechanism
Vijayasaradhi Setaluri1
Defects in autophagy have implications for melanocyte survival and manifesta-
tions of skin pigmentary disorders. Zhang et al. (2015) show that mouse
melanocytes lacking the autophagy protein Atg7 undergo premature senescence
in vitro and accumulate products of oxidative damage, despite activation of the
redox response. Interestingly, contrary to previous findings, the melanocyte-
specific deficiency in autophagy did not cause major defects in melanosome
biogenesis, nor did it produce visually striking changes in mouse coat color.
Journal of Investigative Dermatology (2015) 135, 1215–1217; doi:10.1038/jid.2015.19
In this study, to test the role of autop-
hagy in melanocytes, Zhang et al.
(2015) deleted Atg7 specifically in
melanocytes using floxed- Atg7 and
Tyr::Cre mice. Autophagy, often thought
to be activated in response to cellular
See related article on pg 1348
1Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin, USA
Correspondence: Vijayasaradhi Setaluri, Department of Dermatology, University of Wisconsin-Madison,
Room 439, MSC, 1300 University Avenue, Madison, Wisconsin 53706, USA.
E-mail: vsetaluri@dermatology.wisc.edu
COMMENTARY
www.jidonline.org 1215
